Avian influenza overview: Difference between revisions

Jump to navigation Jump to search
Line 24: Line 24:


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
Following exposure to the [[avian influenza virus]], an incubation period of 2 to 3 days for [[H5N1]] and 2 to 8 days for H7N9 delays the onset of symptoms. The majority of patients present with with a high grade [[fever]], [[cough]], [[headache]], [[sore throat]], [[vomiting]], [[diarrhea]], and [[abdominal pain]]. Approximately 50% of patients with avian influenza develop severe complications such as [[acute respiratory distress syndrome]], [[renal failure]], [[sepsis]], and [[multiple organ dysfunction syndrome]]. Of the reported cases, about 60% of patients have died, particularly those who develop early complications. Patients without complicated disease usually recover within 3 to 5 days with no sequelae.
==Diagnosis==
==Diagnosis==
===History and Symptoms===
===History and Symptoms===

Revision as of 17:51, 23 April 2015

Avian influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Avian influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Avian influenza overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Avian influenza overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Avian influenza overview

CDC on Avian influenza overview

Avian influenza overview in the news

Blogs on Avian influenza overview

Directions to Hospitals Treating Avian influenza

Risk calculators and risk factors for Avian influenza overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D., Synonyms and keywords:, Gerald Chi, M.D.

Overview

Historical Perspective

Avian influenza was first described by Perroncito in 1878 in northern Italy following an outbreak of contagious disease of poultry. In 1918, the avian-descended influenza A H1N1 caused the first major human influenza pandemic. The first avian influenza A H5N1 virus infection in humans was described in 1997 in Hong Kong, where 18 cases were documented (including 6 deaths). The first human-to-human transmission of avian influenza infection was described in 2003 during the outbreaks in Southeast and Central Asia.

Pathophysiology

Classification

To date, only influenza type A has been associated with avian influenza. Neither influenza B nor influenza C is associated with avian influenza. Classification of avian influenza may be based on either the pathogenicity of the virus (low pathogenicity vs. high pathogenicity) or the viral genetic subtypes (H5 vs. H7 vs. H9).

Cause

Avian influenza is caused by influenza A virus. Neither influenza B nor influenza C causes avian influenza. Influenza belongs to the Orthomyxoviridae family. Influenza is an enveloped, pleomorphic (spherical and filamentous forms) virus that contains a linear, segmented (8 segments), negative-sense, single-stranded RNA genome. The genome is composed of 8 segmented genes that encode 11 proteins.

Differential Diagnosis

Avian influenza should be differentiated from the following diseases or pathogens that cause upper or lower respiratory tract infection or flu-like illness, such as other influenza viruses, such as human or swine influenza, other viral, bacterial, fungal, and parasitic agents that are typically associated with nasopharyngeal and respiratory tract infections, and non-infectious causes, such as asthma, chronic obstructive pulmonary disease (COPD), drug adverse effects, and cardiac causes.

Epidemiology and Demographics

The World Health Organization (WHO) reports an incidence of 3 to 5 million cases of severe influenza disease annually, including 250,000 to 500,000 deaths every year. The case fatality rate per outbreak is highly variable and may range from less than 1 to more than 200 per 100,000 cases. Influenza may infect patients of all age groups, but elderly patients > 65 years, young children (especially patients < 2 years of age), and adolescents are at high risk of developing complications and death. There is no racial or gender predilection for avian influenza infection.

Risk Factors

The majority of cases of avian influenza infection in humans have resulted from contact with infected poultry, or contaminated environments. Human to human transmission is still rare and inefficient.

Natural History, Complications, and Prognosis

Following exposure to the avian influenza virus, an incubation period of 2 to 3 days for H5N1 and 2 to 8 days for H7N9 delays the onset of symptoms. The majority of patients present with with a high grade fever, cough, headache, sore throat, vomiting, diarrhea, and abdominal pain. Approximately 50% of patients with avian influenza develop severe complications such as acute respiratory distress syndrome, renal failure, sepsis, and multiple organ dysfunction syndrome. Of the reported cases, about 60% of patients have died, particularly those who develop early complications. Patients without complicated disease usually recover within 3 to 5 days with no sequelae.

Diagnosis

History and Symptoms

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

References

Template:WH Template:WS